NanoViricides, Inc. entered a securities purchase agreement with a single institutional investor on July 24, 2026. The registered direct offering expects to generate approximately $3.8 million in gross proceeds.
The deal consists of 2,516,339 shares of common stock or pre-funded warrants. Each share includes an accompanying warrant to purchase one additional share.
These warrants carry an exercise price of $1.75 per share. They will expire five and a half years after the date of issuance.
The offering is expected to close on or about July 27, 2026, subject to customary conditions. D. Boral Capital LLC is acting as the exclusive placement agent for the transaction.